This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Stocks Set to Soar on Bullish Earnings

Pacira Pharmaceuticals

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

My final earnings short-squeeze candidate is biotechnology and drugs player Pacira Pharmaceuticals (PCRX - Get Report), which just released numbers on Tuesday morning. This is a pharmaceutical company engaged in the development, commercialization, and manufacture of pharmaceutical products for hospitals and ambulatory surgery centers.

Pacira Pharma missed Wall Street estimates for the fourth quarter after reporting a loss of 72 cents vs. the consensus for a loss of 54 cents. Revenue was slightly better than Wall Street estimates at $4.23 million vs. the consensus of $4.05 million. The company also said that it expects to initiate the commercial launch of Exparel in the U.S. during the week of April 9. Exparel was approved by the FDA in October 2011.

The current short interest as a percentage of the float for Pacira Pharmaceuticals is pretty high at 12.6%. That means that out of the 12.08 million shares in the tradable float, 1.83 million are sold short by the bears. The bears have also been increasing their bets from the last reporting period by 2.7%, or by about 48,000 shares.

From a technical perspective, PCRX is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock has found some decent buying interest over the last two months at around $10 a share. The stock has also been making higher highs and higher lows over those two months, which is bullish price action. Now PCRX is trading within range of a big breakout trade post-earnings.

If you're bullish on PCRX, I would look for long-biased trades after its report if it can manage to break out above $12.01 to $12.10 a share with high-volume. Look for volume that registers close to or above its three-month average volume of 126,650 shares. If we get that action, I would then add to any long positions once PCRX takes out $13 a share with volume. A move over $13 will give PCRX a great chance to re-test its all-time high of $15.34 in the near future.

I would simply avoid PCRX or look for short-biased trades after its report if the stock fails to break out and then drops below $10, and its 200-day moving average of $9.68 a share with high-volume. Target a drop back towards $8.50 a share or lower if the bears hammer this down post-earnings.

To see more potential earnings short squeeze plays, including Sealy (ZZ), Family Dollar Stores (FDO) and Charming Shoppes (CHRS), check out the Earnings Short Squeeze Plays portfolio on Stockpickr.

-- Written by Roberto Pedone in Winderemere, Fla.


Follow Stockpickr on Twitter and become a fan on Facebook.
At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Windermere, Fla., is an independent trader who focuses on stocks, options, futures, commodities and currencies. He is also an outside contributor to and maintains the website, which he sold to Blue Wave Advisors in 2008. Roberto studied International Business at The Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany.
6 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
LNN $76.64 0.24%
PVH $96.91 1.37%
OXM $66.00 -0.63%
PCRX $50.51 -6.65%
SNX $81.46 -1.34%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs